Castle Biosciences (CSTL) Invested Capital (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Invested Capital data on file, last reported at $471.5 million in Q1 2026.

• Quarterly Invested Capital rose 4.7% year-over-year to $471.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $471.5 million (up 4.7% YoY) and the FY2025 annual result came in at $480.9 million, up 3.24% from the prior year.
• Invested Capital slipped to $471.5 million in Q1 2026 per CSTL's latest filing, from $480.9 million in the prior quarter.
• The five-year high for Invested Capital was $480.9 million in Q4 2025, with the low at $378.8 million in Q2 2023.
• Average Invested Capital over 5 years is $429.4 million, with a median of $421.7 million recorded in 2022.
• Year-over-year, Invested Capital declined 10.17% in 2023 and advanced 19.06% in 2024.
• Castle Biosciences' Invested Capital stood at $399.2 million in 2022, then fell by 1.97% to $391.3 million in 2023, then increased by 19.06% to $465.9 million in 2024, then rose by 3.24% to $480.9 million in 2025, then retreated by 1.96% to $471.5 million in 2026.
• Business Quant data shows CSTL's Invested Capital at $471.5 million in Q1 2026, $480.9 million in Q4 2025, and $477.1 million in Q3 2025.